Infectious complications during programmed therapy for multiple myeloma
https://doi.org/10.36604/1998-5029-2024-94-71-79
Abstract
Introduction. Monitoring infectious complications during the programmed therapy of hematological malignancies remains a critical issue in modern hematology. Aim. To examine the frequency and nature of infectious complications in patients with multiple myeloma (MM) treated at the Irkutsk Regional Clinical Hospital from 2016 to 2023. Materials and methods. A total of 450 medical records of MM patients who underwent programmed chemotherapy (CT) from 2016 to 2023 were analyzed. Among these, 213 patients (47%) were diagnosed with various infectious complications. These patients were divided into two groups: Group 1 consisted of 100 patients who received CT from 2016 to 2019, while Group 2 included 113 patients treated from 2020 to 2023. Results. The most common infectious complications associated with MM were bacterial pneumonia (41% in 2016-2019 and 18% in 2020-2023), fever of unknown origin (20% in 2016-2019 and 22% in 2020-2023), urinary tract infections (20% in 2016-2019 and 8.8% in 2020-2023), cytomegalovirus (CMV) infection (9% in 2016-2019 and 18.5% in 2020-2023), and in 2020-2023, the emergence of novel coronavirus infection (observed in 17% of MM patients). The majority of infectious complications occurred during the remission induction phase. A significant decrease in bacterial pneumonia (p<0.001) and urinary tract infections (p=0.020) was observed in 2020-2023 compared to 2016-2019, while an increase in CMV infection was noted (p=0.045). Other infectious complications, including gastrointestinal infections, mucositis, herpes infections, and skin and ENT infections, were infrequently reported during the study period. Conclusion. The study revealed new data that can be used to predict the development of infectious complications at various stages of programmed therapy for MM and to formulate effective preventive measures in clinical practice.
About the Authors
N. R. Solovkova
State Budgetary Healthcare Institution Irkutsk Regional Clinical Hospital, winner of the “Mark of the Honor” award
Russian Federation
Russian Federation
Natalya R.Solovkova, Hematologist of Hematology and Chemotherapy Department of Day Hospital
100 Yubileyny Dst., Irkutsk, 664049
V. V. Voitsekhovsky
Federal State Budgetary Educational Institution of Higher Education «Amur State Medical Academy» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Valeriy V. Voytsekhovskiy, MD, PhD, DSc (Med.), Professor, Head of Department of Hospital Therapy with Pharmacology Course
95 Gor'kogo Str., Blagoveshchensk, 675000
References
1. Mendeleeva L.P., Votyakova O.M., Rekhtina I.G., Osmanov E.A., Pod-dubnaya I.V., Grivtsova L.Yu., Falaleeva N.A., Baykov V.V., Kovrigina A.M., Nevolskikh A.A., Ivanov S.A., Khailova Zh.V., Gevorkyan T.G. [Multiple myeloma. Clinical recommendations]. Sovremennaya onkologiya = Modern oncology 2020; 22(4):6–28 (in Russian). https://doi.org/10.26442/18151434.2020.4.200457
2. Bessmeltsev S.S., Karyagina E.V., Ilyushkina E.Yu., Stolypina Zh.L., Miftakhova R.R., Kostroma I.I., Shelkovskaya T.L. [Clinical efficacy of daratumumab in monotherapy of relapsed and refractory multiple myeloma]. Klinicheskaya onkogematologiya = Clinical oncohematology 2020; 13(1):25–32 (in Russian). https://doi.org/10.21320/2500-2139-2020-13-1-25-32
3. Semochkin S.V. [Mechanisms of action of antitumor immunomodulators – from teratogenicity to therapy of multiple myeloma]. Gematologiya i transfuziologiya = Russian journal of hematology and transfusiology 2022; 67(2):240–260 (in Russian). https://doi.org/10.35754/0234-5730-2022-67-2-240-260
4. Luchinin A.S., Semochkin S.V. [Very good partial remission is a predictor of progression-free survival in patients with multiple myeloma]. Onkogematologiya = Oncohematology 2024; 19(1):51–55 (in Russian). https://doi.org/10.17650/1818‑8346‑2024‑19‑1‑51‑55
5. Rukavitsyn O.A., editor. [Hematology: National Guide]. Moscow: GEOTAR-Media; 2019 (in Russian). ISBN: 978-5-9704-3327-0.
6. de la Rubia J., Cejalvo M.J., Ribas P. Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past? Leuk. Lymphoma. 2015; 57(2):258–268. https://doi.org/10.3109/10428194.2015.1088647
7. Bessmeltsev S.S., Abdulkadyrov K.M. [Multiple myeloma: hand. for doctors.]. Moscow: MK; 2016 (in Russian). ISBN: 978-5-91894-051-8.
8. Rios-Tamayo R., Sainz J., Martinez-Lopez J., Puerta J.M., Chang D.Y.L., Rodriguez T., Garrido R., de Veas.J.L.G., Romero A., Moratalla L., López-Fernández E., González P.A., Sánchez M.J., Jiménez-Moleón, J.J., Jurado M., Lahuerta J.J. Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients. Am. J. Hematol. 2016; 91(7):700–704. https://doi.org/10.1002/ajh.24389. PMID: 27074204
9. Teh B.W., Slavin M.A., Harrison S.J., Worth L.J. Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. Expert Rev. Anti-Infect Ther. 2015; 13(11):325–1336. https://doi.org/10.1586/14787210.2015.1083858
10. Novikova A.A., Klyasova G.A., Gribanova E.O. Ryzhko V.V., Mendeleeva L.P., Savchenko V.G. [Infectious complications in patients with multiple myeloma during the first course of chemotherapy]. Onkogematologiya = Oncohematology 2018; 13(3):63–75 (in Russian). https://doi.org/10.17650/1818-8346-2018-13-3-63-75
11. Voitsekhovsky V.V., Landyshev Yu.S., Grigorenko A.A., Tseluiko S.S., Goborov N.D. [Multiple myeloma. modern principles of diagnosis and treatment]. Blagoveshchensk: Polisfera; 2012 (in Russian).
12. Voytsekhovskiy V.V., Zabolotskikh T.V., Grigorenko A.A., Filatova Ye.A. [Bronchopulmonary complications of chronic leukemia]. Blagoveshchensk: Dal'GAU; 2019 (in Russian).
13. Savchenko V.G. editor. [Diagnostic algorithms and treatment protocols for diseases of the blood system (Vol.2)]. Moscow: NMIC Gematologii; 2018 (in Russian). ISBN 978-5-89816-164-4.
14. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5(6):649–655.
15. Poddubny I.V. editor. [Management of oncohematological patients during the COVID-19 pandemic]. Moscow: «Ekonom-Inform»; 2022 (in Russian).
16. Rumyantsev A.G., Maschan A.A., Samochatova E.V. [Accompanying therapy and infection control in hematological and oncological diseases: a guide for doctors]. Moscow: «Medpraktika-M», 2009 (in Russian). ISBN 978-5-98803-173-4
Review
For citations:
Solovkova N.R., Voitsekhovsky V.V. Infectious complications during programmed therapy for multiple myeloma. Bulletin Physiology and Pathology of Respiration. 2024;(94):71-79. (In Russ.) https://doi.org/10.36604/1998-5029-2024-94-71-79
Views:
66
Email this article 